A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| GSK121 trifluoroacetate salt | GSK121 is an inhibitor for protein arginine deiminase 4 (PAD4), which has been shown to inhibit the citrullination of PAD4 target proteins in a functional assay with an IC50 value of 3.2 μM. Synonyms: (3-amino-1-piperidinyl)[1-methyl-2-(1-methyl-1H-indol-2-yl)-1H-benzimidazol-5-yl]-methanone, 2,2,2-trifluoroacetate. Grades: ≥98%. CAS No. 1652591-80-4. Molecular formula: C23H25N5O·CF3COOH. Mole weight: 501.5. |  |
| GSK126 | GSK126 is a potent and highly selective S-adenosyl-methionine-competitive small molecule inhibitor of EZH2 methyltransferase enzyme activity. The inhibition activity of GSK126 on EZH2 activity may provide a promising treatment for EZH2 mutant lymphoma. Group: Biochemicals. Alternative Names: N-[(1,2-Dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-3-methyl-1-[(1S)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-Indole-4-carboxamide; N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-((1S)-1-methylpropyl)-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide. Grades: Highly Purified. CAS No. 1346574-57-9. Pack Sizes: 5mg. US Biological Life Sciences. |  Worldwide |
| GSK126 | GSK126 is a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity. GSK126 decreases global H3K27me3 levels and reactivates silenced PRC2 target genes. GSK126 effectively inhibits the proliferation of EZH2 mutant DLBCL cell lines and markedly inhibits the growth of EZH2 mutant DLBCL xenografts in mice. Together, these data demonstrate that pharmacological inhibition of EZH2 activity may provide a promising treatment for EZH2 mutant lymphoma. Synonyms: GSK2816126; GSK-2816126; GSK 2816126; GSK-126; GSK 126; (S)-1-(sec-Butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide. Grades: 98%. CAS No. 1346574-57-9. Molecular formula: C31H38N6O2. Mole weight: 526.69. | |
| GSK126 | GSK126 Inhibitor. Uses: Scientific use. Product Category: T2079. CAS No. 1346574-57-9. |  |
| GSK-1268992 | GSK-1268992 is one of a metabolite of Pazopanib which is a selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. Synonyms: GSK-1268992; GSK1268992; GSK 1268992; Pazopanib metabolite M24;5-((4-((3-(Hydroxymethyl)-2-methyl-indazol-6-yl)-methyl-amino)pyrimidin-2-yl)amino)-2-methyl-benzenesulfonamide. Grades: 98%. CAS No. 1414375-49-7. Molecular formula: C21H23N7O3S. Mole weight: 453.52. | |
| GSK-1268997 | GSK-1268997 is one of a metabolite of Pazopanib which is a selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. Synonyms: GSK-1268997; GSK1268997; GSK 1268997; Pazopanib metabolite M26; 5-((4-((2,3-Dimethylindazol-6-yl)-methyl-amino)pyrimidin-2-yl)amino)-2-(hydroxymethyl)benzenesulfonamide. Grades: 98%. CAS No. 1414375-50-0. Molecular formula: C21H23N7O3S. Mole weight: 453.52. | |
| GSK-1292263 | GSK1292263 is a novel GPR119 receptor agonist used for the treatment of type 2 diabetes. Synonyms: GSK1292263; GSK 1292263l; GSK-1292263. Grades: 0.98. CAS No. 1032823-75-8. Molecular formula: C23H28N4O4S. Mole weight: 456.561. | |
| GSK1324726A | GSK1324726A is a novel, potent and selective small molecule inhibitor of BET proteins with high affinity to BRD2 (IC50 = 41 nM), BRD3 (IC50 = 31 nM), and BRD4 (IC50 = 22 nM). Synonyms: I-BET-726; I-BET 726; I-BET726; GSK-1324726A; GSK 1324726A. Grades: >98%. CAS No. 1300031-52-0. Molecular formula: C25H23ClN2O3. Mole weight: 434.91. | |
| GSK1324726A | GSK1324726A Inhibitor. Uses: Scientific use. Product Category: T6021. CAS No. 1300031-52-0. | |
| GSK1324726A (I-BET726) | Cas No. 1300031-52-0. | |
| GSK137647A | GSK137647A, a diarylsulfonamide, is an agonist of the free fatty acid receptor 4 [GPR120 (pEC50s = 6.3, 6.2, and 6.1 at human, mouse, and rat receptors, respectively)]. Uses: A selective ffa4 agonist. Synonyms: GSK137647A; GSK-137647A; GSK 137647A; GSK137647; GSK-137647; GSK 137647; 4-methoxy-N-(2,4,6-trimethylphenyl)-benzenesulfonamide. Grades: ≥98%. CAS No. 349085-82-1. Molecular formula: C16H19NO3S. Mole weight: 305.4. | |
| GSK143 | GSK143 is a selective SYK inhibitor, which abrogates survival signals in chronic lymphocytic leukaemia. Synonyms: 2-{[(3r,4r)-3-Aminotetrahydro-2h-Pyran-4-Yl]amino}-4-[(4-Methylphenyl)amino]pyrimidine-5-Carboxamide. CAS No. 1240390-27-5. Molecular formula: C17H22N6O2. Mole weight: 342.40. | |
| GSK 143 dihydrochloride | | |
| GSK-1440115 | GSK-1440115 is an orally active urotensin II receptor antagonist. It is used for the treatment of asthma. Uses: Gsk-1440115 is used for the treatment of asthma. Synonyms: GSK 1440115; GSK-1440115; GSK1440115. 4'-(1-(((6,7-Dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetyl)(methyl)amino)-2-(4-morpholinyl)ethyl)-4-diphenylcarboxylic acid;4-[4-[(1R)-1-[[2-(6,7-dichloro-3-oxo-1,4-benzoxazin-4-yl)acetyl]-methylamino]-2-morpholin-4-ylethyl]phenyl]benzoic acid. Grades: >98 %. CAS No. 1003878-16-7. Molecular formula: C30H29Cl2N3O6. Mole weight: 598.47. | |
| GSK1521498 | GSK-1521498 is a novel μ-Opioid receptor antagonist. It shows to attenuate reward-driven compulsive behaviours, such as stimulant drug seeking or binge eating in animals and humans. It is mainly used for the treatment of obesity and alcohol dependence. It was developed by GlaxoSmithKline and in clinic phase 2. Uses: Gsk-1521498 is mainly used for the treatment of obesity and alcohol dependence. Synonyms: GSK-1521498; GSK1521498; GSK 1521498; GSK-1521498B;N-[[2,6-difluoro-4-[3-(1H-1,2,4-triazol-5-yl)phenyl]phenyl]methyl]-2,3-dihydro-1H-inden-2-amine;N-((3,5-difluoro-3'-(1H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)-2,3-dihydro-1H-inden-2-amine. Grades: >98 %. CAS No. 1007573-18-3. Molecular formula: C24H20F2N4. Mole weight: 402.44. | |
| GSK1521498 free base | GSK1521498 free base is a potent and selective μ-opioid receptor (MOR) antagonist. GSK1521498 free base has the potential for disorders of compulsive consumption of food, alcohol, and agents [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1007573-18-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-115066. |  |
| GSK 1562590 hydrochloride | GSK 1562590 hydrochloride is a high affinity and selective urotensin II (UT) receptor antagonist (pKi = 9.14, 9.28, 9.34, 9.64 and 9.66 at monkey, human, mouse, cat and rat recombinant receptors, respectively). It displays selectivity for UT receptors over a range of GPCRs, ion channels, enzymes and neurotransmitter transporters. GSK 1562590 has been shown to inhibit human urotensin-II (hU-II)-induced contraction of isolated rat aorta in vitro and ex vivo. Synonyms: GSK 1562590 hydrochloride; GSK1562590 hydrochloride; GSK-1562590 hydrochloride; N-[(1R)-1-[3'-(Aminocarbonyl)[1,1'-biphenyl]-4-yl]-2-(1-pyrrolidinyl)ethyl]-6,7-dichloro-2,3-dihydro-N-methyl-3-oxo-4H-1,4-benzoxazine-4-acetamide hydrochloride; 3-[4-[(1R)-1-[[2-(6,7-dichloro-3-oxo-1,4-benzoxazin-4-yl)acetyl]-methylamino]-2-pyrrolidin-1-ylethyl]phenyl]benzamide hydrochloride. Grades: ≥98% by HPLC. CAS No. 1003878-07-6. Molecular formula: C30H30Cl2N4O4.HCl. Mole weight: 617.95. | |
| GSK 1562590 hydrochloride | GSK 1562590 hydrochloride is a high affinity and selective antagonist of urotensin-II receptor (UT) , with pK i s of 9.14-9.66 for mammalian recombinant (mouse, rat, cat, monkey, human) and native UT [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1003878-07-6. Pack Sizes: 1 mg; 5 mg; 10 mg; 50 mg. Product ID: HY-108446. | |
| GSK163090 | GSK163090 is Potent, selective, and orally active 5-HT1A/B/D receptor antagonist. Synonyms: 1-(3-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)phenyl)imidazolidin-2-one; GSK163090; GSK-163090; GSK 163090. Grades: 98%. CAS No. 844903-58-8. Molecular formula: C25H29N5O. Mole weight: 415.54. | |
| GSK 1702934A | GSK 1702934A is a potent and selective TRPC3/6 activator (EC50 = 80 and 440 nM for TRPC3 and 6, respectively). However, it exhibits no activity at TRPV4, TRPA1, M1, M4, CaV1.2, hERG, NaV1.5, or CXCR5 receptors at concentrations <10 μM. Synonyms: 1,3-Dihydro-1-[1-[(5,6,7,8-tetrahydro-4H-cyclohepta[b]thien-2-yl)carbonyl]-4-piperidinyl]-2H-benzimidazol-2-one; 3-[1-(5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-2-carbonyl)piperidin-4-yl]-1H-benzimidazol-2-one; GSK-2934A. Grades: ≥98% by HPLC. CAS No. 924377-85-5. Molecular formula: C22H25N3O2S. Mole weight: 395.52. | |
| GSK172981 | This molecular is a novel non-peptide tachykinin NK3 receptor antagonist and it has a very high affinity for native guinea pig (pK(I) value 7.8) tachykinin NK(3) receptors and recombinant human (pK(I) value 7.7). Meanwhile, GSK172981 also exhibited a competitive profile in antagonizing neurokinin B-stimulated neuronal activity recorded from the guinea pig medial habenula slices (apparent pK(B)=8.1). In the near future, this active molecular may be promising drug candidate in the treatment of schizophrenia. Uses: Treatment of schizophrenia. Synonyms: GSK172981; GSK-172981; GSK 172981. (S)-3-amino-N-(cyclopropyl(phenyl)methyl)-2-(3-fluorophenyl)quinoline-4-carboxamide. Grades: 98%. CAS No. 1133705-99-3. Molecular formula: C26H22FN3O. Mole weight: 411.48. | |
| GSK180736A | GSK180736A is a potent and selective inhibitor of GRK2 (IC50 = 0.77 μM) and ROCK1 (IC50 = 14 nM). Synonyms: GSK-180736A; 4-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxamide. Grades: >98%. CAS No. 817194-38-0. Molecular formula: C19H16FN5O2. Mole weight: 365.37. | |
| GSK1838705A | GSK1838705A is a small-molecule kinase inhibitor that inhibits IGF-IR and IR (insulin receptor) with IC50s of 2.0 and 1.6 nM, respectively. GSK1838705A blocks the in vitro proliferation of cell lines derived from solid and hematologic malignancies, including multiple myeloma and Ewing's sarcoma, and retards the growth of human tumor xenografts in vivo. Despite the inhibitory effect of GSK1838705A on insulin receptor, minimal effects on glucose homeostasis were observed at efficacious doses. GSK1838705A also inhibits the anaplastic lymphoma kinase (ALK), which drives the aberrant growth of anaplastic large-cell lymphomas, some neuroblastomas, and a subset of non-small cell lung cancers. GSK1838705A inhibits ALK, with an IC(50) of 0.5 nmol/L, and causes complete regression of ALK-dependent tumors in vivo at well-tolerated doses. GSK1838705A is therefore a promising antitumor agent for therapeutic use in human cancers. Synonyms: GSK1838705A; GSK-1838705A; GSK-1838705A. Grades: 0.98. CAS No. 1116235-97-2. Molecular formula: C27H29FN8O3. Mole weight: 532.57. | |
| GSK1842799 | GSK1842799 is a selective S1P1 receptor agonist for multiple sclerosis. It showed subnanomole S1P1 agonist activity with >1000× selectivity over S1P3 upon phosphorylation. It has good oral bioavailability. It was selected as a candidate for further clinical on the basis of the favorable in vitro ADME and in vivo PK/PD properties as well as broad toxicology evaluations. Uses: Gsk1842799 was selected as a candidate for further clinical. Synonyms: (S)-2-amino-2-(5-(4-(octyloxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propan-1-ol;GSK1842799; GSK 1842799; GSK 1842799. Grades: >98 %. CAS No. 1005407-76-0. Molecular formula: C20H28F3N3O2S. Mole weight: 431.52. | |
| GSK-189254 | Cas No. 945493-87-8. | |
| GSK 189254A | GSK-189,254 is a H3 histamine receptor inverse agonist. It has subnanomolar affinity for the H3 receptor with Ki of 0.2nM. It possesses stimulant and nootropic effects and analgesic action suggesting a role for H3 receptors in pain processing in the spinal cord. No development was reported about Phase-II clinical trials for Narcolepsy in Europe. Uses: Narcolepsy. Synonyms: 6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-Pyridinecarboxamide. Grades: 98%. CAS No. 720690-73-3. Molecular formula: C21H25N3O2. Mole weight: 351.44. | |
| GSK-189254 free base | GSK-189254 is a potent and selective H3-receptor inverse agonist. It has subnanomolar affinity for the H3 receptor and selectivity of over 10,000x for H3 over other histamine receptor subtypes. Animal studies have shown it to possess not only stimulant and nootropic effects, but also analgesic action suggesting a role for H3 receptors in pain processing in the spinal cord. GSK-189,254 and several other related drugs are currently being investigated as a treatment for Alzheimer's disease and other forms of dementia, as well as possible use in the treatment of conditions such as narcolepsy, or neuropathic pain which do not respond well to conventional analgesic drugs. Group: Agonists. Alternative Names: GSK189254; GSK-189254; GSK 189254; GSK-189254 free base. CAS No. 720690-73-3. Molecular formula: C21H25N3O2. Mole weight: 351.45. Appearance: solid powder. Purity: >98%. IUPACName: 6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)oxy)-N-methylnicotinamide. Canonical SMILES: O=C (NC)C1=CN=C (OC2=CC=C3CCN (C4CCC4)CCC3=C2)C=C1. Catalog: ACM720690733. |  |
| Gsk1904529a | Heterocyclic Organic Compound. Alternative Names: GSK1904529A;GSK1904529A : IGF-IR, IGF-IIR inhibitor;N-(2,6-Difluorophenyl)-5-[3-[2-[[5-ethyl-2-(methyloxy)-4-[4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]imidazo[1,2-a]pyridin-2-yl]-2-(methyloxy)benzamide;GSK 4529;N-(2,6-difluorophenyl)-5-(3-(2-(5-ethyl-2-methoxy-4-(4-(4-(methylsulfonyl)piperazin-1-yl)piperidin-1-yl)phenylamino)pyrimidin-4-yl)H-imidazo[1,2-a]pyridin-2-yl)-2-methoxybenzamide;N-(2,6-Difluorophenyl)-5-[3-[2-[[5-ethyl-2-(methyloxy)-4-[4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]imidazo[1,2-a]pyridin-2-yl]-2-(methyloxy)benzamideGSK 1904529A;GSK1904529A, >=98%;IGF-IR, IGF-IIR inhibitor. CAS No. 1089283-49-7. Molecular formula: C44H47F2N9O5S. Density: 1.39. Catalog: ACM1089283497. | |
| GSK-1904529a | GSK-1904529A is an IGF-1R Inhibitor, is is a promising candidate for therapeutic use in IGF-IR-dependent tumors. GSK1904529A selectively inhibits IGF-IR and IR with IC50s of 27 and 25 nmol/L, respectively. GSK1904529A blocks receptor autophosphorylation and downstream signaling, leading to cell cycle arrest. It inhibits the proliferation of cell lines derived from solid and hematologic malignancies, with multiple myeloma and Ewing's sarcoma cell lines being most sensitive. Oral administration of GSK1904529A decreases the growth of human tumor xenografts in mice, consistent with a reduction of IGF-IR phosphorylation in tumors. Despite the potent inhibitory activity of GSK1904529A on IR in vitro and in vivo, minimal effects on blood glucose levels are observed in animals at doses that show significant antitumor activity. Synonyms: GSK 4529; GSK4529; GSK-4529; GSK1904529a; GSK 1904529; GSK-1904529a. CAS No. 1089283-49-7. Molecular formula: C44H47F2N9O5S. Mole weight: 851.975. | |
| GSK1904529A | GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) , with IC 50 s of 27 and 25 nM, respectively. GSK1904529A shows poor activity ( IC 50 >1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1089283-49-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-10524. | |
| GSK1997132B | PPARγ is a ligand-activated nuclear receptor and was reported to plays a role in energy metabolism, glucose homeostasis and microglia-mediated neuroinflammation. GSK1997132B is a metabolically stable, highly potent centrally penetrant PPARγ partial agonist. Synonyms: GSK 1997132B; GSK-1997132B; GSK1997132B; GSK1997132; GSK-1997132; GSK 1997132. (R)-1-((3,5-difluoropyridin-2-yl)methyl)-2-methyl-N-(1-phenylpropyl)-1H-benzo[d]imidazole-5-carboxamide. Grades: 98%. CAS No. 1168138-37-1. Molecular formula: C24H22F2N4O. Mole weight: 420.46. | |
| GSK199 hydrochloride | GSK199 is a potent and reversible inhibitor of PAD4 with an IC50 value of 200 nM) which is less potent than the related PAD4 inhibitor GSK484 (IC50 = 50 nM). Synonyms: [(3R)-3-amino-1-piperidinyl][2-(1-ethyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzimidazol-5-yl]-methanone, monohydrochloride. Grades: ≥98%. CAS No. 1549811-53-1. Molecular formula: C24H28N6O2·HCl. Mole weight: 469. | |
| GSK2018682 | GSK2018682 is an agonist for S1P1 and S1P5 receptor with pEC 50 s of 7.7 and 7.2, respectively, and has no agonist activity towards human S1P2, S1P3, or S1P4. GSK2018682 is used in the research of multiple sclerosis. Uses: Scientific research. Group: Signaling pathways. CAS No. 1034688-30-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-19511. | |
| GSK-2018682 | GSK-2018682 is a potent and selective agonist of sphingosine-1-phosphate receptor (S1PR) subtype 1 that has the potential to treat multiple sclerosis (MS). Synonyms: GSK2018682; GSK 2018682; GSK-2018682. UNII-NJL503AIJA; NJL503AIJA; 4-(4-(5-(5-chloro-6-isopropoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl)-1H-indol-1-yl)butanoic acid. Grades: ≥98%. CAS No. 1034688-30-6. Molecular formula: C22H21ClN4O4. Mole weight: 440.884. | |
| GSK-2033 | GSK-2033 is a potent cell-active LXR antagonist (pIC50 = 7.5). It enhances T-cell proliferation and blocks T 0901317-antiproliferative activity on T-cells and is cell permeable. Group: Antagonists. Alternative Names: GSK-2033; GSK2033; GSK 2033. CAS No. 1221277-90-2. Molecular formula: C29H28F3NO5S2. Mole weight: 591.66. Appearance: Solid powder. Purity: >98%. IUPACName: 2, 4, 6-Trimethyl-N-[[3'- (methylsulfonyl) [1, 1'-biphenyl]-4-yl]methyl]-N-[[5- (trifluoromethyl) -2-furanyl]methyl]benzenesulfonamide. Canonical SMILES: O=S (C1=C (C)C=C (C)C=C1C) (N (CC2=CC=C (C3=CC=CC (S (=O) (C)=O)=C3)C=C2)CC4=CC=C (C (F) (F)F)O4)=O. Catalog: ACM1221277902. | |
| GSK-2033 | This active molecular is a cell permeable, potent LXR (liver-X-receptor) antagonist. pIC50 values is 7.0 for LXRα and 7.4 for LXR&beta. GSK2033 enhances T-cell proliferation and Th1/Th2/Th17 differentiation when treatment of murine CD41 T cells. Synonyms: GSK-2033; GSK2033; GSK 2033; CHEMBL1093266;GTPL8690; SCHEMBL13280409;2,4,6-trimethyl-N-[[4-(3-methylsulfonylphenyl)phenyl]methyl]-N-[[5-(trifluoromethyl)furan-2-yl]methyl]benzenesulfonamide. Grades: 98%. CAS No. 1221277-90-2. Molecular formula: C29H28F3NO5S2. Mole weight: 591.66. | |
| GSK2110183 | GSK2110183 is an orally bioavailable pan-Akt inhibitor with IC50s of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively. Synonyms: GSK2110183; GSK 2110183; GSK-2110183. Grades: >98%. CAS No. 1047634-63-8. Molecular formula: C18H16Cl2F2N4OS. Mole weight: 445.31. | |
| GSK2141795 hydrochloride | GSK2141795 Hcl is a potent and selective pan-Akt inhibitor with IC50s of 180/328/38 nM for Akt1/Akt2/Akt3 respectively. Synonyms: GSK-2141795 Hydrochloride; GSK 2141795 Hydrochloride; GSK2141795 Hydrochloride; GSK2141795 HCl; Uprosertib. Grades: >98%. CAS No. 1047635-80-2. Molecular formula: C18H17Cl3F2N4O2. Mole weight: 465.71. | |
| GSK215083 | GSK215083 is a PET radioligand for the 5-hydroxytrypamine-6 (5HT6) receptor. It is a quinoline based compounds that acts by antagonising the 5-HT6 receptor. It binds to receptors 5HT6 in the striatum and 5-hydroxytryptamine-2A (5HT2A) in the frontal cortex. It is used for the treatment of Alzheimer's disease and used as a PET ligand for identification of occupancy of the 5HT6 receptor coupled with 11C. Uses: Gsk215083 is used for the treatment of alzheimer's disease and used as a pet ligand for identification of occupancy of the 5ht6 receptor coupled with 11c. Synonyms: GSK-215083; GSK 215083; GSK215083; 3-(3-Fluoro-benzenesulfonyl)-8-(4-Methyl-piperazin-1-yl)-quinoline;GSK-215083;Quinoline, 3-((3-fluorophenyl)sulfonyl)-8-(4-methyl-1-piperazinyl)-. Grades: 98%. CAS No. 607742-80-3. Molecular formula: C20H20FN3O2S. Mole weight: 385.46. | |
| GSK2190915 | GSK2190915 is a potent FLAP(5-Lipoxygenase-activating protein) inhibitor. It exhibits excellent preclinical toxicology and pharmacokinetics in rat and dog. It also demonstrated an extended pharmacodynamic effect in a rodent bronchoalveolar lavage (BAL) model. It increased survival time in mice exposed to a lethal intravenous injection of platelet activating factor (PAF). Synonyms: AM-803; AM 803; AM803; 3Fiboflapon; GSK2190915; GSK 2190915; GSK-2190915. Grades: >98%. CAS No. 936350-00-4. Molecular formula: C38H43N3O4S. Mole weight: 637.83. | |
| GSK2190915 sodium salt | GSK2190915(AM-803; Fiboflapon) sodium salt is a potent FLAP(5-Lipoxygenase-activating protein) inhibitor with binding IC50 of 2.9 nM. Synonyms: GSK2190915 sodium salt; GSK 2190915 sodium salt; GSK-2190915 sodium salt; GSK-2190915A; GSK 2190915A; GSK2190915A; Fiboflapon sodium; AM-803 sodium; AM 803 sodium; AM803 sodium. Grades: >98%. CAS No. 1196070-26-4. Molecular formula: C38H42N3NaO4S. Mole weight: 659.81. | |
| GSK2190915 (sodiuM salt) | GSK2190915 (sodiuM salt). CAS No. 1196070-26-4. Catalog: ACM1196070264. | |
| GSK2193874 | GSK2193874 is a potent, orally active and specific antagonist of TRPV4 ion channels (IC50 values 2 and 40 nM for rat and human receptors, respectively). GSK2193874 is selective over a panel of ~200 human receptors, channels and enzymes. Synonyms: GSK2193874; GSK 2193874; GSK-2193874; GSK2193874A; GSK 2193874A; GSK-2193874A; 7-bromo-N-(1-phenylcyclopropyl)-3-[(4-piperidin-1-ylpiperidin-1-yl) methyl]-2-[3-(trifluoromethyl)phenyl]quinoline-4-carboxamide. CAS No. 1336960-13-4. Molecular formula: C37H38BrF3N4O. Mole weight: 691.62. | |
| GSK2194069 | GSK2194069 is a fatty acid synthase (FAS) inhibitor. GSK2194069 is a potent and specific inhibitor of the β-ketoacyl reductase (KR) activity of hFAS with an IC50 of 7.7 ± 4.1 nM for the overall hFAS reaction. FAS is upregulated in some cancers, including prostate cancer. GSK2194069 was found to inhibit tumour growth in prostate cancer C42b cell xenografts generated in Nod-SCID-gamma mice. Cellular FAS inhibition reduced cell growth were also demonstrated in non-small-cell lung (A549) cancer cell lines with an average EC50 of 15 ± 0.5 nM. Synonyms: GSK 2194069; GSK-2194069. Grades: >98%. CAS No. 1332331-08-4. Molecular formula: C25H24N4O3. Mole weight: 428.48. | |
| GSK2245035 | GSK2245035 is a highly potent and selective intranasal Toll-Like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN)-stimulating properties. GSK2245035 has pEC 50 s of 9.3 and 6.5 for IFNα and TFN&alpha. GSK2245035 effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood cell cultures. GSK2245035 is used for asthma [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1207629-49-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-118250. | |
| GSK2245035 | This active molecular is a selective TLR7 (Toll-like receptor 7) agonist with preferential Type-1 IFN-stimulating properties which is under development of GlaxoSmithKline. GSK2245035 displays potent IFNα inducing potency and IFNα/TNFα selectivity. In Aug 2015, GlaxoSmithKline completed a phase II follow-up trial for Allergic asthma and Allergic rhinitis in Canada. In Jul 2016, GlaxoSmithKline planed a phase II trial for Allergic asthma in Germany (Intranasal). Uses: Allergic asthma; allergic rhinitis. Synonyms: GSK2245035; GSK 2245035; GSK-2245035; (S)-6-amino-2-(pentan-2-yloxy)-9-(5-(piperidin-1-yl)pentyl)-7,9-dihydro-8H-purin-8-one;1325212-97-2 (maleate salt). Grades: 98%. CAS No. 1207629-49-9. Molecular formula: C20H34N6O2. Mole weight: 390.52. | |
| GSK 2250665A | GSK 2250665A is an Itk inhibitor (pKi = 9.2) displaying selectivity for Itk over Aurora B kinase and Btk (pIC50 = 6.4 and 6.5, respectively) and a panel of other kinases. GSK 2250665A was shown to inhibit IFNγ production in PBMCs. Synonyms: GSK-2250665A; GSK 2250665A; GSK2250665A; GSK-2250665; GSK 2250665; GSK2250665; trans-4-[[4-[(6-Ethyl-2-benzothiazolyl)amino]-6-(phenylmethyl)-2-pyrimidinyl]amino]cyclohexanol. Grades: ≥97% by HPLC. CAS No. 1246030-96-5. Molecular formula: C26H29N5OS. Mole weight: 459.61. | |
| GSK2256098 | GSK2256098 is a selective FAK kinase inhibitor, which inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Uses: Scientific research. Group: Signaling pathways. CAS No. 1224887-10-8. Pack Sizes: 10 mM * 1 mL; 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100498. | |
| GSK-2256098 | GSK2256098, also known as GTPL7939, is a focal adhesion kinase-1 (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. Synonyms: GSK2256098; GSK 2256098; GSK-2256098; GTPL7939; GTPL-7939; GTP L7939. Grades: 98%. CAS No. 1224887-10-8. Molecular formula: C20H23ClN6O2. Mole weight: 414.89. | |
| GSK-2256098 hydrochloride | GSK-2256098 hydrochloride is a focal adhesion kinase (FAK) inhibitor that exhibits potential antiangiogenic and antineoplastic activities. GSK-2256098 hydrochloride targets FAK to inhibit tumor cell growth by regulating cell adhesion, migration, proliferation, and survival. Uses: Scientific research. Group: Signaling pathways. CAS No. 1416771-10-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-100498A. | |
| GSK2256294A | GSK2256294A, an effective inhibitor of human soluble epoxide hydrolase(sEH), was developed by GSK and still under Phase I trial in Chronic obstructive pulmonary disease. IC50: 27pM. Uses: Gsk2256294a is an effective inhibitor of human soluble epoxide hydrolase(seh). Synonyms: GSK2256294; GSK-2256294; GSK 2256294; GSK2256294A; GSK-2256294A; GSK 2256294A. UNII-L33EX3XR0T; GSK2256294A; L33EX3XR0T; SCHEMBL2677671; GSK 2256294A. Grades: 98%. CAS No. 1142090-23-0. Molecular formula: C21H24F3N7O. Mole weight: 447.46. | |
| GSK-2262167 hydrate | GSK-2262167 is a potent S1P3-sparing and S1P1 agonist and has a potent activity is in a collagen-induced arthritis model as efficacious as fingolimod and shows excellent pharmacokinetic properties preclinically. Uses: Arthritis. Synonyms: GSK-2262167 sodium; GSK 2262167 sodium; GSK2262167 sodium; sodium 3-(6-(5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl)-5-methyl-3,4-dihydroisoquinolin-2(1H)-yl)propanoate. Grades: ≥98%. CAS No. 1458576-13-0. Molecular formula: C25H28N4O5. Mole weight: 464.51. | |
| GSK-2262167 sodium | This molecular is a potent S1P3-sparing and S1P1 agonist. Meanwhile GSK-2262167 has a potent activity is in a collagen-induced arthritis model as efficacious as fingolimod and shows excellent pharmacokinetic properties preclinically. Uses: Arthritis. Synonyms: GSK-2262167 sodium; GSK 2262167 sodium; GSK2262167 sodium; sodium 3-(6-(5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl)-5-methyl-3,4-dihydroisoquinolin-2(1H)-yl)propanoate,1165924-28-6 (free acid); 458576-13-0 (hydrate). Grades: 98%. CAS No. 1165923-54-5. Molecular formula: C25H25N4NaO4. Mole weight: 468.49. | |
| GSK2269557 | GSK2269557, an effective PI3K inhibitor, could be used as against inflammatory and some autoimmune diseases. It has just completes a phase II trial against Asthma. Uses: Gsk2269557 is an effective pi3k inhibitor that could be used as against inflammatory and some autoimmune diseases. Synonyms: CHEMBL2216859; GSK2269557 (free base); GSK2269557; GSK-2269557; GSK 2269557; Nemiralisib; 2-(6-(1H-indol-4-yl)-1H-indazol-4-yl)-5-((4-isopropylpiperazin-1-yl)methyl)oxazole; 6-(1H-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole. Grades: 95%. CAS No. 1254036-71-9. Molecular formula: C26H28N6O. Mole weight: 440.54. | |
| GSK-2269557 HCl salt | GSK-2269557 is a selective Phosphatidylinositol 3 kinase delta inhibitor originated by GlaxoSmithKline. GSK-2269557 is highly selective for PI3Kδ over the closely related isoforms and is active in a animal model of Th2-driven lung inflammation. Treatment for Asthma and Chronic obstructive pulmonary disease(COPD) is in clinical trials Phase II. Uses: Asthma; chronic obstructive pulmonary disease. Synonyms: GSK-2269557 HCl salt; GSK 2269557 HCl salt; GSK2269557 HCl salt; 6-(1H-indol-4-yl)?-4-[5-[[4-(1-methylethyl)?-1-piperazinyl]?methyl]?-2-oxazolyl]?-1H-indazole, monohydrochloride;1254036-71-9(free base). Grades: 98%. CAS No. 1254036-77-5. Molecular formula: C26H28N6O HCl. Mole weight: 477.01. | |
| GSK2292767 | GSK2292767 is a Phosphatidylinositol 3 kinase delta inhibitor applicated for the treatment of respiratory diseases including asthma and COPD in clinical trials. GSK2292767 is highly selective for PI3Kδ over the closely related isoforms and is really active in the animal model of Th2-driven lung inflammation. Uses: Asthma and copd. Synonyms: GSK2292767; GSK-2292767; GSK 2292767. N-[5-[4-[5-[[(2R, 6S)-2, 6-dimethylmorpholin-4-yl]methyl]-1, 3-oxazol-2-yl]-1H-indazol-6-yl]-2-methoxypyridin-3-yl]methanesulfonamide; SCHEMBL173490; ZINC95938263; KB-78330; 1254036-66-2; Methanesulfonamide, N-[5-[4-[5-[[(2R, 6S)-2, 6-dimethyl-4-morpholinyl]methyl]-2-oxazolyl]-1H-indazol-6-yl]-2-methoxy-3-pyridinyl]. Grades: 98%. CAS No. 1254036-66-2. Molecular formula: C24H28N6O5S. Mole weight: 512.58. | |
| GSK2330672 | GSK-2330672, an ASBT inhibitor, has been developed for the treatment of type 2 diabetes and is currently under Phase II trail against primary biliary cirrhosis and type 2 diabetes. IC50: 42 ± 3 nM. Uses: Gsk-2330672 is an asbt inhibitor that has been developed for the treatment of type 2 diabetes and is currently under phase ii trail against primary biliary cirrhosis and type 2 diabetes. Synonyms: CHEMBL2387408; UNII-386012Z45S; GSK2330672; GSK-2330672; SCHEMBL2586025; CZGVOBIGEBDYTP-VSGBNLITSA-N. Grades: 98%. CAS No. 1345982-69-5. Molecular formula: C28H38N2O7S. Mole weight: 546.68. | |
| GSK2334470 | GSK2334470 is a potent 3-phosphoinositide-dependent protein kinase (PDK1) inhibitor (IC50 ~ 10 nM), which does not suppress the activity of 93 other protein kinases including 13 AGC-kinases most related to PDK1 at 500-fold higher concentrations. GSK2334470 also inhibited T-loop phosphorylation and activation of Akt. GSK2334470 will be a useful tool for delineating the roles of PDK1 in biological processes. Synonyms: GSK2334470; GSK2334470; GSK2334470. Grades: 0.98. CAS No. 1227911-45-6. Molecular formula: C25H34N8O. Mole weight: 462.602. | |
| GSK239512 | GSK239512 is a potent and brain penetrated H 3 receptor antagonist. GSK239512 can be used for the research of mild-to-moderate Alzheimer's disease (AD) [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 720691-69-0. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-106000. | |
| GSK-239512 | GSK-239512 is a histamine H3 receptor antagonist. In Jun 2015, Phase-II for Schizophrenia in USA was discontinued. Phase II clinical trilas for the treatment of Multiple sclerosis are on-going. Uses: Multiple sclerosis. Synonyms: GSK-239512; GSK239512; GSK 239512; 1-(6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-3-pyridinyl)-2-Pyrrolidinone. Grades: 98%. CAS No. 720691-69-0. Molecular formula: C23H27N3O2. Mole weight: 377.48. | |
| GSK256066 | GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380,000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold selectivity against PDE4B versus PDE7. Synonyms: GSK256066; GSK 256066; GSK-256066. Grades: >98%. CAS No. 801312-28-7. Molecular formula: C27H26N4O5S. Mole weight: 518.58. | |
| GSK256066 2,2,2-trifluoroacetic acid | GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380,000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold selectivity against PDE4B versus PDE7. Synonyms: GSK-256066; GSK 256066. Grades: >98%. CAS No. 1415560-64-3. Molecular formula: C29H27F3N4O7S. Mole weight: 632.61. | |
| GSK256073 | GSK256073 Inhibitor. Uses: Scientific use. Product Category: T15432. CAS No. 862892-90-8. | |
| GSK256471 | This active molecular is a selective and potent NK(3) antagonist. It has a high affinity for recombinant human (pK(I) value 8.9) and native guinea pig (pK(I) value 8.4) tachykinin NK(3) receptors. In the near future, GSK256471 may be potentially very useful in the treatment of schizophrenia. Uses: Treatment of schizophrenia. Synonyms: GSK256471; GSK-256471; GSK 256471. N-[ (S)-cyclopropyl (phenyl)methyl]-3-[[methyl (methylsulfonyl)amino]methyl]-2-phenylquinoline-4-carboxamide. Grades: 98%. CAS No. 1133706-08-7. Molecular formula: C29H29N3O3S. Mole weight: 499.63. | |
| GSK2578215A | Potent leucine-rich repeat kinase 2 (LRRK2) inhibitor (IC50 values are 8.9 and 10.1nm respectively for LRRK2[G2019S] mutant and wild-type LRRK2 respectively). Displays selectivity for LRRK2 against a panel of 460 other kinases. Blocks Ser910 and Ser935 phosphorylation in vitro and in peripheral tissues in vivo. Brain penetrant. Group: Biochemicals. Alternative Names: 5-(2-Fluoro-4-pyridinyl)-2-(phenylm ethoxy)-N-3-pyridinylbenzamide. Grades: Highly Purified. CAS No. 1285515-21-0. Pack Sizes: 10mg, 25mg. US Biological Life Sciences. | Worldwide |
| GSK2578215A | GSK2578215A induces a dose-dependent inhibition of Ser910 and Ser935 phosphorylation in both wild-type LRRK2 and LRRK2[G2019S] stably transfected into HEK293 cells. Synonyms: GSK2578215A; GSK-2578215A; GSK 2578215A. Grades: >98%. CAS No. 1285515-21-0. Molecular formula: C24H18FN3O2. Mole weight: 399.42. | |
| GSK2578215A | GSK2578215A is a potent and highly selective LRRK2 inhibitor, which exhibits IC 50 s of around 10 nM against both wild-type LRRK2 and the G2019S mutant. Uses: Scientific research. Group: Signaling pathways. CAS No. 1285515-21-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13237. | |
| GSK2578999A | GSK2578999A is a potent HIV-1 maturation inhibitor with IC50 values of 17 nM, 23 nM, 25 nM, and 8 nM for wild type, Q369H, V370A, and T371A respectively. Synonyms: GSK-8999; (3β)-3-(3-carboxy-3-methyl-1-oxobutoxy)-N-[1-(4-chlorophenyl)cyclopropyl]-α,21-dioxo-28-norlup-18-ene-17-acetamide. CAS No. 1422355-59-6. Molecular formula: C46H62ClNO7. Mole weight: 776.4. | |
| GSK 2606414 | GSK 2606414 is a potent and selective PERK inhibitor that suppresses PERK activation in cells and inhibits the growth of a human tumor xenograft in mice. Protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states. Evidence that PERK is implicated in tumorigenesis and cancer cell survival stimulated our search for small-molecule inhibitors. Synonyms: GSK2606414; GSK-2606414; GSK 2606414; GSK PERK Inhibitor. 1-(5-(4-Amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-indolin-1-yl)-2-(3-(trifluoromethyl)phenyl)ethanone. Grades: 98%. CAS No. 1337531-36-8. Molecular formula: C24H20F3N5O. Mole weight: 451.453. | |
| GSK 2606414 | GSK 2606414. Group: Biochemicals. Alternative Names: 7-Methyl-5-[1-[[3- (trifluoromethyl) phenyl]acetyl]-2, 3-dihydro-1H-indol-5-yl]-7H-pyrrolo[2, 3-d]pyrimidin-4-amine. Grades: Highly Purified. CAS No. 1337531-36-8. Pack Sizes: 1mg. Molecular Formula: C24H22F3N5O, Molecular Weight: 453.46. US Biological Life Sciences. | Worldwide |
Our database is helping our users find suppliers everyday.
